NCT04878211View on ClinicalTrials.gov

A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

PHASE4TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 10, 2021

Primary Completion Date

April 14, 2023

Study Completion Date

April 14, 2023

Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
DRUG

Ofatumumab

3 loading doses followed by monthly administrations

BIOLOGICAL

mRNA COVID-19 vaccine

Pfizer or Moderna mRNA Vaccine

DRUG

interferon or glatiramer acetate

iDMT

Trial Locations (7)

28204

The Neurological Institute PA, Charlotte

33024

Infinity Clinical Research LLC ., Hollywood

45459

Dayton Center for Neurological Disorders, Centerville

55446

Minnesota Center Multiple Sclerosis, Plymouth

63131

The MS Center for Innovation in Care, St Louis

85032

Center For Neurology and Spine, Phoenix

02481

Dragonfly Research LLC, Wellesley

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY